In this episode of Make Medicines Affordable, Tracy Swan speaks with AVAC’s Executive Director, Mitchell Warren, about the rollout of long-acting injectable HIV prevention with lenacapavir, across African countries.

They explore both the extraordinary promise of this breakthrough, and the fragile systems it depends on. Recent data show steep declines in HIV testing and PrEP access following major funding disruptions, raising urgent concerns about the future of prevention services.

Mitchell explains why lenacapavir’s success will depend not just on science, but on strong health systems, political will, and equitable access, especially for key populations and low- and middle-income countries beyond Africa.

A timely conversation on innovation, inequality, and what it will take to turn scientific progress into real-world impact.